Table 1 The demographic characteristics, underlying diseases, and mortality rates among non-HIV patients with PJP according to pulmonary CMV infection status
CMV-DNA positive in BALF (n = 38) | CMV-DNA negative in BALF(n = 32) | p | |
|---|---|---|---|
Demographics | |||
Age, yr., median | 51(21–77) | 48(22–81) | 0.48 |
Gender ratio(male:female) | 23:15 | 20:12 | 0.87 |
Underlying diseases,n(%) | |||
Solid organ transplantation | 3(7.9) | 3(9.4) | 1.00 |
Hematologic malignancy | 4(10.5) | 9(28.2) | 0.06 |
Hematopoietic stem cell transplantation | 3(75) | 4(44.4) | |
Non-hematologic malignancy | 2(5.3) | 2(6.3) | 1.00 |
Dermatologic diseases | 4(10.5) | 5(15.6) | 0.78 |
Kidney disease | 12(31.5) | 5(15.6) | 0.12 |
Interstitial lung disease | 0(0) | 1(3.1) | 1.00 |
Connective tissue disease | 9(23.7) | 5(15.6) | 0.40 |
Idiopathic thrombocytopenia | 2(5.3) | 1(3.1) | 1.00 |
Others | 2(5.3) | 1(3.1) | 1.00 |
Immunosuppressive agents,n(%) | |||
Steroids | 37(97.4) | 31(96.9) | 1.00 |
Dosage of steroid, recent 1 month(mg) | 40(10–100) | 45(10–300) | 0.54 |
Steroid + T-cell immunosuppressants | 28(73.7) | 15(65.2) | 0.02 |
Steroid +Anti-CD20+ monoclonal antibodya | 1(2.6) | 6(18.8) | 0.06 |
Chemotherapy/Radiotherapy | 2(5.3) | 3(9.4) | 0.84 |
Treatment for PJP | |||
TMP-SMZ(%) | 33(86.8) | 31(96.9) | 0.29 |
Treatment duration, days, median | 15(4–31) | 21(2–23) | 0.051 |
Shift to second-line therapyb(%) | 23(60.5) | 12(37.5) | 0.055 |
Due to treatment failure | 18(47.4) | 11(34.4) | 0.27 |
Due to adverse reactionc | 5(13.2) | 1(3.1) | 0.29 |
Morbidity,n(%) | |||
Admitted to ICU | 16(42.1) | 9(28.2) | 0.22 |
Mechanical ventilation | 14(36.8) | 8(25.0) | 0.29 |
Mortality | 17(44.7) | 9(28.2) | 0.15 |